# Ovagen

> Ovagen is a synthetic tripeptide, L-glutamyl-L-aspartyl-L-leucine (Glu-Asp-Leu), with the formula C15H25N3O8 and a molecular weight of 375.37 g/mol. It is grouped with the short peptide bioregulators. No peer-reviewed studies on this peptide were found in PubMed as of October 2026, so its biological activity is undocumented in the indexed literature. It is not an FDA-approved drug.

Canonical: https://peptideproperties.com/compounds/ovagen/

## Identity

- **Class:** Short Peptide Bioregulators
- **Also known as:** Glu-Asp-Leu
- **Molecular formula:** C15H25N3O8
- **Molecular weight:** 375.37 g/mol
- **Monoisotopic mass:** 375.1642 Da
- **PubChem CID:** 444128
- **InChIKey:** JVSBYEDSSRZQGV-GUBZILKMSA-N
- **Sequence:** EDL
- **Sequence notes:** No modifications; free N-terminal amine and free C-terminal carboxylic acid.

## Key facts

- Class: short peptide bioregulator; synthetic tripeptide
- Sequence: H-Glu-Asp-Leu-OH (EDL), three residues
- Formula C15H25N3O8; molecular weight 375.37 g/mol (PubChem CID 444128)
- PubChem lists no CAS number; record title glutamyl-aspartyl-leucine
- Peer-reviewed studies on this peptide in PubMed: none found as of October 2026
- Regulatory status: not approved by the FDA

## What Is Ovagen?

Ovagen is the tripeptide Glu-Asp-Leu, a synthetic short peptide grouped with the peptide bioregulators. It consists of three standard amino acids, L-glutamic acid, L-aspartic acid and L-leucine, linked in that order.No peer-reviewed studies on this peptide were found in PubMed as of October 2026. Searches for the name return papers on an unrelated product instead, described below. As a result, this page reports only identity and composition facts from PubChem and does not describe biological effects, mechanisms or study findings.

## Chemical Structure and Molecular Identity

Ovagen is a linear tripeptide with a free N-terminal amine on glutamic acid and a free C-terminal carboxylic acid on leucine. PubChem (CID 444128) lists the molecular formula C15H25N3O8, a molecular weight of 375.37 g/mol and the InChIKey JVSBYEDSSRZQGV-GUBZILKMSA-N. The record is titled glutamyl-aspartyl-leucine, and PubChem lists no CAS number for it.The molecule is polar, with a computed XLogP of -3.6. Two of its three residues carry acidic side chains, while the C-terminal leucine adds a branched, nonpolar side chain. The PubChem formula matches the unmodified sequence Glu-Asp-Leu.
### Related sequences
Several bioregulator peptides share a Glu-Asp core. Ovagen's full sequence appears as residues 2 to 4 of bronchogen (Ala-Glu-Asp-Leu), and chonluten (Glu-Asp-Gly) and pinealon (Glu-Asp-Arg) differ from it only in the third residue. These are separate compounds with different formulas and molecular weights.

## What the Published Literature Covers

No peer-reviewed studies on the Glu-Asp-Leu peptide called Ovagen were found in PubMed as of October 2026. There are no indexed reports of its effects in cell culture, animals or humans, and no published data on mechanisms, pharmacokinetics or toxicology.A PubMed search for the name does return results, but they concern something else: an ovine follicle-stimulating hormone (FSH) preparation sold under the same name and used in reproduction research in sheep, goats and cattle. That hormone is a large glycoprotein, not a tripeptide, and studies of it provide no information about the Glu-Asp-Leu peptide. Readers searching the literature should screen results carefully for this name collision.Claims about organ-specific activity for this peptide are not supported by any peer-reviewed study identified for this page. Related peptides such as bronchogen or chonluten have their own small literatures, but their findings cannot be transferred to Ovagen.With no published studies and a shared product name, researchers typically confirm Ovagen's identity with mass spectrometry and HPLC data on a certificate of analysis.

## Regulatory and Research Status

Ovagen is not approved by the US Food and Drug Administration and is handled as a research compound in the United States. It has no published clinical, animal or cell-culture record in PubMed, so its research status is limited to chemical identity. Basic properties such as stability in solution, activity in cell systems and safety have not been described in peer-reviewed sources.Because the name is shared with an unrelated veterinary hormone preparation and the sequence closely resembles other Glu-Asp peptides, identity verification matters. Researchers typically confirm that material matches the formula C15H25N3O8 and a molecular weight of 375.37 g/mol.

## FAQ

**What is the sequence of Ovagen?**
Ovagen is the tripeptide Glu-Asp-Leu (one-letter code EDL): L-glutamic acid, L-aspartic acid and L-leucine, with a free N-terminal amine and a free C-terminal carboxylic acid. PubChem (CID 444128) lists its formula as C15H25N3O8 and its molecular weight as 375.37 g/mol, consistent with that unmodified sequence.

**Is Ovagen the same as the FSH product called Ovagen?**
No. The bioregulator Ovagen is the small tripeptide Glu-Asp-Leu. The same name is also used for an ovine follicle-stimulating hormone preparation that appears in sheep, goat and cattle reproduction studies. That hormone is a large glycoprotein, and its research literature says nothing about the tripeptide.

**Is Ovagen FDA approved?**
No. The tripeptide Ovagen (Glu-Asp-Leu) is not approved by the US Food and Drug Administration for any use and is handled as a research compound in the United States. No peer-reviewed studies on it were found in PubMed as of October 2026, including no human clinical trials.

**What does the research on Ovagen show?**
No peer-reviewed research on the Glu-Asp-Leu peptide called Ovagen was found in PubMed as of October 2026. Its documented properties are limited to chemical identity: formula C15H25N3O8, molecular weight 375.37 g/mol and PubChem CID 444128. Effects reported for related peptides cannot be attributed to it.